Skip to main content
Premium Trial:

Request an Annual Quote

Accelr8 Gets Listing Extension from NYSE Alternext

NEW YORK (GenomeWeb News) – Accelr8 today said that it has received a notice from the NYSE Alternext exchange informing the firm that it has granted a listing extension based on a plan submitted by the firm to regain compliance with listing regulations by July 6, 2010.

The Denver-based assay instrument developer was informed by the Alternext in January that it was not in compliance with certain listing standards concerning its amount of stockholder equity, and that it must submit and implement a plan to regain compliance within 18 months.

Accelr8 said today that it has provided the exchange with a plan to show how it intends to regain compliance with a rule that its stockholders' equity equal or exceed $6 million, and for continuing operations and net income to reverse from losses sustained in its five most recent fiscal years.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.